Skip To Content
Fast Forward

Ashkenazi Jews With Crohn’s Disease More Likely To Have Parkinson’s Gene: Study

Ashkenazi Jews with Crohn’s disease have an increased likelihood of carrying a gene mutation that causes Parkinson’s disease, a new scientific study has found.

The study, published in Science Translational Medicine, could help doctors better understand the causes of both Parkinson’s and Crohn’s, a disease causing chronic inflammation of the digestive system that is disproportionately prevalent among Ashkenazi Jews.

The decade-long study found that Ashkenazi Jews with Crohn’s are more likely to have the LRRK2 gene mutation, which the Michael J. Fox Foundation calls the greatest known genetic contributor to Parkinson’s.

“The presence of shared LRRK2 mutations in patients with Crohn’s disease and Parkinson’s disease provides refined insight into disease mechanisms and may have major implications for the treatment of these two seemingly unrelated diseases,” explained lead researcher Inga Peter, Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai in New York City.

Dr. Peter and her colleagues analyzed 23,000 genetic mutations in 2,066 Ashkenazi Jews with Crohn’s and 3,633 Ashkenazi Jews who don’t have Crohn’s.

The analysis also found that Crohn’s patients with a riskier version of the LRRK2 mutation were more likely to develop Crohn’s in the small intestine, which is harder to treat. Crohn’s patients with the riskier LRRK2 mutation also developed the disease an average of six years earlier than patients who did not have that mutation.

Contact Aiden Pink at [email protected] or on Twitter, @aidenpink

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.